Prognostic role of p27(Kip1) and apoptosis in human breast cancer

British Journal of Cancer

Volumn 79, Issue 9-10, 1999, Pages 1572-1578

  Wu, J ^a   Shen, Z Z ^a   Lu, J S ^a   Jiang, M ^a   Han, Q X ^a   Fontana, J A ^b   Barsky, S H ^c   Shao, Z M ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Al; Breast cancer; p27(Kip1); p53; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN P27; PROTEIN P53; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; RISK FACTOR; TREATMENT INDICATION; ANALYSIS OF VARIANCE; BREAST TUMOR; DISEASE FREE SURVIVAL; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ANALYSIS OF VARIANCE; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0032587341     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690250     Document Type: Article

References (33)

1. Allan DJ, Howell A, Roberts SA, Williams GT, Watson RJ, Coyne JD, Clarke RB, Laidlaw IJ and Potten CS (1992) Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J Pathol 167: 25-32
2. Alessandrini A, Chiaur DS and Pagano M (1997) Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11: 342-345
3. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L (1997) Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Medicine 3: 227-230
4. Doglioni C, Pelosio P, Laurino L, Macri E, Meggiolaro E, Favretti F and Barbraeschi M (1996) p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 179: 248-253
5. El-Deiry WS, Tokino T, Veiculescu VE, Levy DB, Parsons R, Trent LM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825
6. El-Deiry WS, Tokino T and Waldman T (1995) Topological control or p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919
7. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M and Giordano A (1997) Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385
8. Geske FJ, Bemis LT, Schedin PJ and Strange R (1994) Function evaluation of genes associated with apoptotic cell death of mammary epithelium. Proc Annu Meet Am Assoc Cancer Res 35: 19-25
9. Gray-Bablin J, Rao S and Keyomarsi K (1997) Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res 57: 604-609
10. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge ST (1993) The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
11. Hartwell L and Kastan MB (1994) Cell cycle control and cancer. Science 266: 1820-1828
12. Hoehner JC. Hedborg F, Wiklund HJ, Olsen L and Pahlman S (1995) Cellular death in neuroblastoma: in situ correlation of apoptosis and bcl-2 expression. Int J Cancer 62: 19-24
13. Hunt T and Nasmyth K (1993) Dams and sluices. Nature (Lond) 366: 634-635
14. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ and Fontana JA (1997) p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 74: 529-534
15. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH and Seth P (1997) Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 57: 5441-5445
16. Kate TE, Shao ZM, Sugg NK, Long RT, Russell GB, Case LD (1992) Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 52: 5198-5203
17. Langlois NE, Lamb J, Eremin O and Heys SD (1997) Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products. J Pathol 182: 302-397
18. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
19. Loda M, Cukor B, Tam SW, Lavin P, Florentino M, Draetta GF, Jessup JM and Pagano M (1997) Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 3: 231-234
20. Marchetti A, Doglioni C and Burbareschi M (1996) p21 mRNA and protein expression in non-small cell lung cancer: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12: 1319-1324
21. Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR (1994) Clonation of senescent cell-derived inhibitors or DNA synthesis using an expression screen. Exp Cell Res 211: 90-98
22. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massague J (1994a) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator or extracellular antimitogenic signals. Cell 78: 59-66
23. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A (1994b) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22
24. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, and Roberts JM (1997) Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 3: 222-225
25. Raff MC (1992) Social controls on cell survival and cell death. Nature 356: 397-400
26. Reynisdottir I, Polyak K, Iavarone A and Massague J (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 9: 1831-1845
27. Robertson J (1997) Prognostic and response markers in the management of breast cancer. Cancer Treatment Rev 23: S41-48
28. Saez S, Clark GM and McGuire WL (1988) Prognostic factors in cancer of the breast. Clin Oncol 2: 103-115
29. Shao Z-M, Jiang M, Wu J, Han Q-X, Zhang T-Q, Shen Z-Z and Fontana JA (1996) Identification or spontaneous programmed cell death during development of human breast cancer. Oncology Rep 3: 1133-1136
30. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M and Loda M (1997) The cell cycle inhibitor p27 is an independent prognostic marker in small (T1 a,b) invasive breast carcinomas. Cancer Res 57: 1259-1263
31. Tomei LD, Kanter P and Wenner CE (1988) Inhibition of radiation-induced apoptosis in vitro by tumor promoters. Biochem Biophys Res Commun 155: 324-331
32. Toyoshima H and Hunter T (1994) p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74
33. Wage S, Hannon GJ, Beach D and Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond) 369: 574-578